304 related articles for article (PubMed ID: 34170403)
1. Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study.
Hänninen K; Viitala M; Atula S; Laakso SM; Kuusisto H; Soilu-Hänninen M
J Neurol; 2022 Feb; 269(2):913-922. PubMed ID: 34170403
[TBL] [Abstract][Full Text] [Related]
2. Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS.
Sorensen PS; Kopp TI; Joensen H; Olsson A; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2021 May; 50():102813. PubMed ID: 33578207
[TBL] [Abstract][Full Text] [Related]
3. Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.
Buron MD; Chalmer TA; Sellebjerg F; Barzinji I; Danny B; Christensen JR; Christensen MK; Hansen V; Illes Z; Jensen HB; Kant M; Papp V; Petersen T; Prakash S; Rasmussen PV; Schäfer J; Theódórsdóttir Á; Weglewski A; Sorensen PS; Magyari M
Neurology; 2020 Aug; 95(8):e1041-e1051. PubMed ID: 32636328
[TBL] [Abstract][Full Text] [Related]
4. Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.
Chalmer TA; Kalincik T; Laursen B; Sorensen PS; Magyari M;
J Neurol; 2019 Feb; 266(2):306-315. PubMed ID: 30515628
[TBL] [Abstract][Full Text] [Related]
5. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.
Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á
Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075
[TBL] [Abstract][Full Text] [Related]
7. Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries.
Hrnciarova T; Drahota J; Spelman T; Hillert J; Lycke J; Kubala Havrdova E; Recmanova E; Adamkova J; Mares J; Libertinova J; Pavelek Z; Hradilek P; Ampapa R; Stetkarova I; Peterka M; Martinkova A; Stourac P; Grunermelova M; Vachova M; Dufek M; Horakova D
Mult Scler Relat Disord; 2023 Aug; 76():104803. PubMed ID: 37329786
[TBL] [Abstract][Full Text] [Related]
8. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
Freeman L; Longbrake EE; Coyle PK; Hendin B; Vollmer T
CNS Drugs; 2022 Dec; 36(12):1285-1299. PubMed ID: 36350491
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia.
Alharbi MA; Aldosari F; Althobaiti AH; Abdullah FM; Aljarallah S; Alkhawajah NM; Alanazi M; AlRuthia Y
BMC Health Serv Res; 2023 May; 23(1):552. PubMed ID: 37237257
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.
Harding K; Williams O; Willis M; Hrastelj J; Rimmer A; Joseph F; Tomassini V; Wardle M; Pickersgill T; Robertson N; Tallantyre E
JAMA Neurol; 2019 May; 76(5):536-541. PubMed ID: 30776055
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison.
Taheri S; Sahraian MA; Yousefi N
J Med Econ; 2019 Jan; 22(1):71-84. PubMed ID: 30380350
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients.
Wang L; Qi CH; Zhong R; Yuan C; Zhong QY
Medicine (Baltimore); 2018 Feb; 97(8):e9908. PubMed ID: 29465579
[TBL] [Abstract][Full Text] [Related]
15. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
Fernández Ó
Mult Scler Relat Disord; 2017 Oct; 17():75-83. PubMed ID: 29055479
[TBL] [Abstract][Full Text] [Related]
16. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies.
Iaffaldano P; Lucisano G; Caputo F; Paolicelli D; Patti F; Zaffaroni M; Brescia Morra V; Pozzilli C; De Luca G; Inglese M; Salemi G; Maniscalco GT; Cocco E; Sola P; Lus G; Conte A; Amato MP; Granella F; Gasperini C; Bellantonio P; Totaro R; Rovaris M; Salvetti M; Torri Clerici VLA; Bergamaschi R; Maimone D; Scarpini E; Capobianco M; Comi G; Filippi M; Trojano M;
Ther Adv Neurol Disord; 2021; 14():17562864211019574. PubMed ID: 34104220
[TBL] [Abstract][Full Text] [Related]
17. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
18. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.
Spelman T; Magyari M; Piehl F; Svenningsson A; Rasmussen PV; Kant M; Sellebjerg F; Joensen H; Hillert J; Lycke J
JAMA Neurol; 2021 Oct; 78(10):1197-1204. PubMed ID: 34398221
[TBL] [Abstract][Full Text] [Related]
19. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study.
Alroughani R; Al-Hashel J; Ahmed SF
Clin Neurol Neurosurg; 2024 May; 240():108249. PubMed ID: 38513425
[TBL] [Abstract][Full Text] [Related]
20. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
